{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:52:46Z","timestamp":1781632366004,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oral tenofovir and emtricitabine taken as pre-exposure prophylaxis (HIV-PrEP) is highly effective at reducing Human Immunodeficiency Virus (HIV) acquisition. Nucleotide analogues have also been shown to inhibit Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) polymerase activity in vitro, raising the question as to whether tenofovir-based HIV-PrEP could be useful for the prevention and treatment of COVID-19. We sought to examine the association between HIV-PrEP use and self-reported COVID-19 testing outcomes and respiratory symptoms among men and gender diverse people who have sex with men in the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants completed online surveys deployed at three time points during the COVID-19 pandemic (Survey 1 (S1) 23\/06\/20\u2009\u2212\u200914\/07\/20; S2 23\/11\/20\u2009\u2212\u200912\/12\/20; S3 23\/03\/21\u2009\u2212\u200914\/04\/21), including men (cis\/transgender), transwomen or gender-diverse people reporting sex with another man (cis\/transgender) or non-binary person assigned male at birth. The outcome was self-reported COVID-19 testing and COVID-19 related respiratory symptoms including a new continuous cough, high temperature or loss of smell and\/or taste during the most recent lookback period. All participants reporting taking HIV-PrEP in the past year were compared with those who did not. Analysis was performed using logistic regression, adjusting for sociodemographic and behavioural factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 4,544 participants living without HIV across three surveys (89.7% of all survey respondents), 21.4% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009970) reported recently using HIV-PrEP, 564 (12.4%) participants reported respiratory symptoms and 160 (3.5%) reported a positive COVID-19 test. There was a slight, non-statistically significant positive association between HIV-PrEP use and a COVID-19 positive test in the first survey-period (P1) (adjusted Odds Ratio (aOR)\u2009=\u20091.11, CI\u2009=\u20090.51\u20133.98). This positive association significantly increased across survey periods (P2: aOR\u2009=\u20094.26, CI\u2009=\u20091.21\u201314.97, P3: aOR\u2009=\u20099.02, CI\u2009=\u20092.69\u201330.31). There was a positive association between HIV-PrEP use and respiratory symptoms in the first survey-period (aOR\u2009=\u20091.45, CI\u2009=\u20091.03\u20132.03). However, this positive association reversed in survey-period 2 and 3 (P2: aOR\u2009=\u20090.62, CI\u2009=\u20090.40\u20130.95, P3: aOR\u2009=\u20090.45, CI\u2009=\u20090.28\u20130.72).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We found no evidence that HIV-PrEP use protected against COVID-19 among participants. Conversely, we identified a positive association between HIV-PrEP use and COVID-19 which may reflect uncaptured behaviours that increase COVID-19 exposure amongst those using HIV-PrEP. The decline in respiratory symptoms in HIV-PrEP users over time might reflect some immune protection following exposures to respiratory viruses through more social mixing or a direct impact of HIV-PrEP on symptom severity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-025-26127-0","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:17:27Z","timestamp":1769105847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PrEPped for COVID? The association between HIV-PrEP use and COVID-19 among men and gender diverse people who have sex with men: findings from three large online surveys in the United Kingdom"],"prefix":"10.1186","volume":"26","author":[{"given":"Caisey V.","family":"Pulford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack RG.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison R.","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenda","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"26127_CR1","unstructured":"World Health Organisation. WHO director-general\u2019s opening remarks at the media briefing on COVID-19. 2020."},{"key":"26127_CR2","unstructured":"GOV.UK, Prime minister\u2019s statement on coronavirus (COVID-19). 2020."},{"issue":"16","key":"26127_CR3","doi-asserted-by":"publisher","first-page":"7367","DOI":"10.1080\/07391102.2021.1901144","volume":"40","author":"DC Copertino Jr","year":"2022","unstructured":"Copertino DC Jr., et al. Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. J Biomol Struct Dyn. 2022;40(16):7367\u201380.","journal-title":"J Biomol Struct Dyn"},{"issue":"4","key":"26127_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25489","volume":"23","author":"N Ford","year":"2020","unstructured":"Ford N, et al. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. J Int AIDS Soc. 2020;23(4):e25489.","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"26127_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13868","volume":"75","author":"M Boban","year":"2021","unstructured":"Boban M. Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. Int J Clin Pract. 2021;75(4):e13868.","journal-title":"Int J Clin Pract"},{"issue":"11","key":"26127_CR6","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","volume":"19","author":"M Chien","year":"2020","unstructured":"Chien M, et al. Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J Proteome Res. 2020;19(11):4690\u20137.","journal-title":"J Proteome Res"},{"issue":"4","key":"26127_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.7326\/L20-1399","volume":"174","author":"J Del Amo","year":"2021","unstructured":"Del Amo J, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy. Ann Intern Med. 2021;174(4):581\u20132.","journal-title":"Ann Intern Med"},{"issue":"7","key":"26127_CR8","doi-asserted-by":"publisher","first-page":"e2005","DOI":"10.1093\/cid\/ciaa1198","volume":"73","author":"A Boulle","year":"2021","unstructured":"Boulle A, et al. Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western cape Province, South Africa. Clin Infect Dis. 2021;73(7):e2005\u201315.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"26127_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa455","volume":"7","author":"O Ayerdi","year":"2020","unstructured":"Ayerdi O, et al. Preventive efficacy of Tenofovir\/Emtricitabine against severe acute respiratory syndrome coronavirus 2 among pre-exposure prophylaxis users. Open Forum Infect Dis. 2020;7(11):ofaa455.","journal-title":"Open Forum Infect Dis"},{"key":"26127_CR10","unstructured":"Pebody R. 1600 people taking PrEP in Scotland and Wales, almost all are gay men. aidsmap, 2018. available: https:\/\/www.aidsmap.com\/news\/apr-2018\/1600-people-taking-prep-scotland-and-wales-almost-all-are-gay-men"},{"key":"26127_CR11","unstructured":"DHSC, HIV drug PrEP to be available across England. 2020. available: https:\/\/www.gov.uk\/government\/news\/hiv-drug-prep-to-be-available-across-england"},{"issue":"1","key":"26127_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmi.2022.07.006","volume":"29","author":"R Polo","year":"2023","unstructured":"Polo R, et al. Daily Tenofovir disoproxil fumarate\/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers. Clin Microbiol Infect. 2023;29(1):85\u201393.","journal-title":"Clin Microbiol Infect"},{"key":"26127_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac188","author":"C Delaugerre","year":"2022","unstructured":"Delaugerre C, et al. Severe acute respiratory syndrome coronavirus 2 seroprevalence among HIV-negative participants using tenofovir\/emtricitabine-based preexposure prophylaxis in 2020: a substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts. Open Forum Infect Dis. 2022. https:\/\/doi.org\/10.1093\/ofid\/ofac188.","journal-title":"Open Forum Infect Dis"},{"key":"26127_CR14","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820002253","volume":"148","author":"DE Fernandes","year":"2020","unstructured":"Fernandes DE, Ferreira PRA, Mastroianni Kirsztajn G. Pre-exposure prophylaxis during the SARS-CoV-2 pandemic: can PrEP prevent COVID-19-related symptoms? Epidemiol Infect. 2020;148:e231.","journal-title":"Epidemiol Infect"},{"issue":"10","key":"26127_CR15","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1093\/cid\/ciad084","volume":"76","author":"AN Lea","year":"2023","unstructured":"Lea AN, et al. Human immunodeficiency virus status, Tenofovir exposure, and the risk of poor coronavirus disease 19 outcomes: real-world analysis from 6 united States cohorts before vaccine rollout. Clin Infect Dis. 2023;76(10):1727\u201334.","journal-title":"Clin Infect Dis"},{"key":"26127_CR16","doi-asserted-by":"publisher","first-page":"100993","DOI":"10.1016\/j.eclinm.2021.100993","volume":"38","author":"JJ Parienti","year":"2021","unstructured":"Parienti JJ, et al. Effect of tenofovir disoproxil fumarate and emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: a pilot, randomized, open-label phase 2 trial. EClinicalMedicine. 2021;38:100993.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"26127_CR17","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.2196\/publichealth.9010","volume":"4","author":"S Wayal","year":"2018","unstructured":"Wayal S, et al. The acceptability and feasibility of implementing a bio-behavioral enhanced surveillance tool for sexually transmitted infections in england: mixed-methods study. JMIR Public Health Surveill. 2018;4(2):e52.","journal-title":"JMIR Public Health Surveill"},{"issue":"8","key":"26127_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/hiv.12753","volume":"20","author":"S Wayal","year":"2019","unstructured":"Wayal S, et al. Association between knowledge, risk behaviours, and testing for sexually transmitted infections among men who have sex with men: findings from a large online survey in the united Kingdom. HIV Med. 2019;20(8):523\u201333.","journal-title":"HIV Med"},{"key":"26127_CR19","volume-title":"Stata statistical software: release 15 college station","author":"StataCorp","year":"2017","unstructured":"StataCorp. Stata Statistical Software: Release 15. College Station. TX: StataCorp LLC; 2017."},{"key":"26127_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/14786440009463897","volume":"1","author":"K Pearson","year":"1900","unstructured":"Pearson K. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. Philos Mag. 1900;1:157\u201375.","journal-title":"Philos Mag"},{"issue":"7","key":"26127_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/sextrans-2020-054768","volume":"97","author":"I Hyndman","year":"2021","unstructured":"Hyndman I, et al. COVID-19 restrictions and changing sexual behaviours in HIV-negative MSM at high risk of HIV infection in London, UK. Sex Transm Infect. 2021;97(7):521\u20134.","journal-title":"Sex Transm Infect"},{"key":"26127_CR22","doi-asserted-by":"crossref","unstructured":"Brown JR et al. Changes in STI and HIV testing and testing need among men who have sex with men during the uk\u2019s COVID-19 pandemic response. Sex Transm Infect, 2022: p. sextrans\u20132022.","DOI":"10.1136\/sextrans-2022-055429"},{"issue":"1","key":"26127_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1186\/s12889-023-15779-5","volume":"23","author":"D Ogaz","year":"2023","unstructured":"Ogaz D, et al. COVID-19 infection and vaccination uptake in men and gender-diverse people who have sex with men in the UK: analyses of a large, online community cross-sectional survey (RiiSH-COVID) undertaken November\u2013December 2021. BMC Public Health. 2023;23(1):829.","journal-title":"BMC Public Health"},{"key":"26127_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-022-02458-6","author":"T Nadarzynski","year":"2023","unstructured":"Nadarzynski T, et al. The impact of first UK-wide lockdown (March-June 2020) on sexual behaviours in men and gender diverse people who have sex with men during the COVID-19 pandemic: a cross-sectional survey. Arch Sex Behav. 2023. https:\/\/doi.org\/10.1007\/s10508-022-02458-6.","journal-title":"Arch Sex Behav"},{"issue":"7","key":"26127_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/OLQ.0000000000001636","volume":"49","author":"DC de Vries","year":"2022","unstructured":"de Vries DC, et al. Barriers and motives for complying with sexual distancing among men who have sex with men during the first COVID-19 pandemic lockdown in amsterdam: A qualitative study. Sex Transm Dis. 2022;49(7):497\u2013503.","journal-title":"Sex Transm Dis"},{"issue":"6","key":"26127_CR26","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/sextrans-2020-054756","volume":"97","author":"T Reyniers","year":"2021","unstructured":"Reyniers T, et al. Reduced sexual contacts with non-steady partners and less PrEP use among MSM in Belgium during the first weeks of the COVID-19 lockdown: results of an online survey. Sex Transm Infect. 2021;97(6):414\u20139.","journal-title":"Sex Transm Infect"},{"issue":"8","key":"26127_CR27","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1007\/s10461-022-03618-4","volume":"26","author":"D Gillespie","year":"2022","unstructured":"Gillespie D, et al. PrEP use, sexual behaviour, and PrEP adherence among men who have sex with men living in Wales prior to and during the COVID-19 pandemic. AIDS Behav. 2022;26(8):2746\u201357.","journal-title":"AIDS Behav"},{"key":"26127_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-022-03788-1","author":"M Holt","year":"2022","unstructured":"Holt M, et al. Adjusting behavioural surveillance and assessing disparities in the impact of COVID-19 on gay and bisexual men\u2019s HIV-related behaviour in Australia. AIDS Behav. 2022. https:\/\/doi.org\/10.1007\/s10461-022-03788-1.","journal-title":"AIDS Behav"},{"issue":"5","key":"26127_CR29","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/sextrans-2021-055039","volume":"98","author":"AR Howarth","year":"2022","unstructured":"Howarth AR, et al. \u2018Stay at home \u2026\u2019: exploring the impact of the COVID-19 public health response on sexual behaviour and health service use among men who have sex with men: findings from a large online survey in the UK. Sex Transm Infect. 2022;98(5):346\u201352.","journal-title":"Sex Transm Infect"},{"issue":"6","key":"26127_CR30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.7555\/JBR.34.20200044","volume":"34","author":"Y Yun","year":"2020","unstructured":"Yun Y, et al. Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification. J Biomed Res. 2020;34(6):458.","journal-title":"J Biomed Res"},{"key":"26127_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173720","volume":"890","author":"HG Toor","year":"2021","unstructured":"Toor HG, et al. Computational drug re-purposing targeting the Spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19. Eur J Pharmacol. 2021;890:173720.","journal-title":"Eur J Pharmacol"},{"key":"26127_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.imu.2021.100531","volume":"23","author":"MR Rahman","year":"2021","unstructured":"Rahman MR, et al. Identification of potential antivirals against SARS-CoV-2 using virtual screening method. Inform Med Unlocked. 2021;23:100531.","journal-title":"Inform Med Unlocked"},{"key":"26127_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117652","volume":"252","author":"B Shah","year":"2020","unstructured":"Shah B, Modi P, Sagar SR. In silico studies on therapeutic agents for COVID-19: drug repurposing approach. Life Sci. 2020;252:117652.","journal-title":"Life Sci"},{"key":"26127_CR34","first-page":"1552","volume":"31","author":"GC Clososki","year":"2020","unstructured":"Clososki GC, et al. Tenofovir disoproxil fumarate: new chemical developments and encouraging in vitro biological results for SARS-CoV-2. J Braz Chem Soc. 2020;31:1552\u20136.","journal-title":"J Braz Chem Soc"},{"key":"26127_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01114-20","author":"S-J Park","year":"2020","unstructured":"Park S-J, et al. Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets. mBio. 2020. https:\/\/doi.org\/10.1128\/mbio.01114-20.","journal-title":"mBio"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-26127-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-26127-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-26127-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:58:44Z","timestamp":1781629124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-025-26127-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["26127"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-26127-0","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval of this study was provided by the University College London (UCL) Research Ethics Committee (ref: 9155\/001). Online informed consent was received from all participants and all methods were performed in accordance with guidelines and regulations set by the UCL Research Ethics Committee. All research was carried out in compliance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"624"}}